Innovative Biomarkers in Oncology

Biomarkers serve as markers for cancer progression and prognosis and represent promising therapeutic targets. Improving our understanding of how cancers originate, grow and spread may help to reduce the risk and burden of the disease. Cancer biomarker research has identified Neuropilin-1 and Semaphorin 4D  as novel protein markers  and promising  therapeutic targets. These proteins can easily be detected in human serum and plasma by ELISA assay.

Innovative Biomarkers in Oncology

Check out our biomarker kits for cancer research link

or have a look at our compete Oncology Biomarker Brochure

√  EASY – ready to use calibrators & controls
√  RELIABLE – full validation package
√  LOW sample volume- 10 µl / sample

Neuropilin-1 ELISA – BI-20409 – Product link

Semaphorin 4D ELISA – BI-20405 – Product link

Innovative Biomarkers in Oncology 

Related publications

Neuropilins Controlling Cancer Therapy Responsiveness. Full text link

Napolitano V, Tamagnone L. Int J Mol Sci. 2019 Apr 25;20(8):2049. doi: 10.3390/ijms20082049. PMID: 31027288. 

Abstract

Neuropilins (NRPs) are cell surface glycoproteins, acting as co-receptors for secreted Semaphorins (SEMAs) and for members of the vascular endothelial growth factor (VEGF) family; they have been initially implicated in axon guidance and angiogenesis regulation, and more recently in cancer progression. In addition, NRPs have been shown to control many other fundamental signaling pathways, especially mediated by tyrosine kinase receptors (RTKs) of growth factors, such as HGF (hepatocyte growth factor), PDGF (platelet derived growth factor) and EGF (epidermal growth factor). This enables NRPs to control a range of pivotal mechanisms in the cancer context, from tumor cell proliferation and metastatic dissemination, to tumor angiogenesis and immune escape. Moreover, cancer treatment failures due to resistance to innovative oncogene-targeted drugs is typically associated with the activity of alternative RTK-dependent pathways; and neuropilins’ capacity to control oncogenic signaling cascades supports the hypothesis that they could elicit such mechanisms in cancer cells, in order to escape cytotoxic stress and therapeutic attacks. Intriguingly, several studies have recently assayed the impact of NRPs inhibition in combination with diverse anti-cancer drugs. In this minireview, we will discuss the state-of-art about the relevance of NRPs as potential predictive biomarkers of drug response, and the rationale to target these proteins in combination with other anticancer therapies.

Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer. Full text link

Mastrantonio R, You H, Tamagnone L. Theranostics. 2021 Jan 15;11(7):3262-3277. doi: 10.7150/thno.54023. PMID: 33537086; PMCID: PMC7847692.

 Abstract

Semaphorins are a large family of developmental regulatory signals, characterized by aberrant expression in human cancers. These molecules crucially control cell-cell communication, cell migration, invasion and metastasis, tumor angiogenesis, inflammatory and anti-cancer immune responses. Semaphorins comprise secreted and cell surface-exposed molecules and their receptors are mainly found in the Plexin and Neuropilin families, which are further implicated in a signaling network controlling the tumor microenvironment. Accumulating evidence indicates that semaphorins may be considered as novel clinical biomarkers for cancer, especially for the prediction of patient survival and responsiveness to therapy. Moreover, preclinical experimental studies have demonstrated that targeting semaphorin signaling can interfere with tumor growth and/or metastatic dissemination, suggesting their relevance as novel therapeutic targets in cancer; this has also prompted the development of semaphorin-interfering molecules for application in the clinic. Here we will survey, in diverse human cancers, the current knowledge about the relevance of semaphorin family members, and conceptualize potential lines of future research development in this field.

Related products

DKK-1 (Dickkopf-1) ELISA kit – BI-20413 –  Product link

√  Direct measurement – no sample pre-dilution
√  CE marked – for IVD use in the EU
√  Day test – all reagents included
√  Widely cited +160 references!

 DKK1 promotes migration and invasion of non-small cell lung cancer via β-catenin signaling pathway. Full text link

Zhang J, Zhang X, Zhao X, Jiang M, Gu M, Wang Z, Yue W Tumour Biol. 2017. 39(7):1010428317703820. doi: 10.1177/1010428317703820. PMID: 28677426.

 Dickkopf-1: A Promising Target for Cancer Immunotherapy. Full text link

Chu HY, Chen Z, Wang L, Zhang ZK, Tan X, Liu S, Zhang BT, Lu A, Yu Y, Zhang G. Front Immunol. 2021 May 20;12:658097. doi: 10.3389/fimmu.2021.658097. PMID: 34093545; PMCID: PMC8174842.

 Leucine-rich alpha-2-glycoprotein (LRG) ELISA kit – BI-LRG1 –  Product link

√  DAY Test – results in 3.5 h
√  RELIABLE – rigorously validated according to FDA/ICH/EMA guidelines
√  ALL reagents included – controls and sufficient amounts of buffers
√  Specific recombinant epitope-mapped antibodies

Leucine-rich α-2-glycoprotein promotes TGFβ1-mediated growth suppression in the Lewis lung carcinoma cell lines. Full text link

Oncotarget. Takemoto N, Serada S, Fujimoto M, Honda H, Ohkawara T, Takahashi T, Nomura S, Inohara H, Naka T. 2015. 10;6(13):11009-22. doi: 10.18632/oncotarget.3557. PMID: 25826092; PMCID: PMC4484435.

Detection of leucine-rich alpha-2-glycoprotein 1-containing immunocomplexes in the plasma of lung cancer patients with epitope-specific mAbs. Abstract link.

Lázár J, Kovács A, Tornyi I, Takács L, Kurucz I. Cancer Biomark. 2021 Nov 1. doi: 10.3233/CBM-210164. Epub ahead of print. PMID: 34744074.

Check out the Biomedica Cytokine ELISA kits using specific recombinant epitope-mapped antibodies:

√  Interleukin-6 (IL-6)  ELISA  –  BI-IL6 – product link
√  Vasular Endothelial Growth Factor (VEGF) ELISA – BI-VEGF –  product link
√  Angiopoietin-2 ELISA  – BI-ANG2 – product link

See our complete Product Brochure Biomarkers in Oncology